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Abstract
Purpose: To examine the in vitro and in vivo efficacy of the dual PI3K/mTOR inhibitor NVP-BEZ235 in treatment of PIK3CA
wild-type colorectal cancer (CRC).
Experimental Design: PIK3CA mutant and wild-type human CRC cell lines were treated in vitro with NVP-BEZ235, and the
resulting effects on proliferation, apoptosis, and signaling were assessed. Colonic tumors from a genetically engineered
mouse (GEM) model for sporadic wild-type PIK3CA CRC were treated in vivo with NVP-BEZ235. The resulting effects on
macroscopic tumor growth/regression, proliferation, apoptosis, angiogenesis, and signaling were examined.
Results: In vitro treatment of CRC cell lines with NVP-BEZ235 resulted in transient PI3K blockade, sustained decreases in
mTORC1/mTORC2 signaling, and a corresponding decrease in cell viability (median IC50=9.0–14.3 nM). Similar effects were
seen in paired isogenic CRC cell lines that differed only in the presence or absence of an activating PIK3CA mutant allele. In
vivo treatment of colonic tumor-bearing mice with NVP-BEZ235 resulted in transient PI3K inhibition and sustained blockade
of mTORC1/mTORC2 signaling. Longitudinal tumor surveillance by optical colonoscopy demonstrated a 97% increase in
tumor size in control mice (p=0.01) vs. a 43% decrease (p=0.008) in treated mice. Ex vivo analysis of the NVP-BEZ235-
treated tumors demonstrated a 56% decrease in proliferation (p=0.003), no effects on apoptosis, and a 75% reduction in
angiogenesis (p=0.013).
Conclusions: These studies provide the preclinical rationale for studies examining the efficacy of the dual PI3K/mTOR
inhibitor NVP-BEZ235 in treatment of PIK3CA wild-type CRC.
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Introduction
In 2011, colorectal cancer (CRC) will continue to be the third
most common cause of cancer-related mortality in the U.S [1].
Despite the growing arsenal of chemotherapeutic agents, the
median survival for patients with metastatic CRC is still less than
20 months, which underscores the urgent need for the develop-
ment of novel therapeutic approaches [2].
Mammalian target of rapamycin (mTOR) is a serine/threonine
kinase that regulates cellular proliferation and apoptosis. mTOR
binds regulatory associated protein of mTOR (Raptor) and
mammalian LST8/G-protein b-subunit like protein (mLST8/
GbL) to form the mTOR complex 1 (mTORC1), which promotes
translation through phosphorylation of p70 S6 kinase (S6K), S6
ribosomal protein (S6), and eukaryotic initiation factor 4E binding
protein 1(4E-BP1). Alternatively, mTOR can bind rapamycin-
insensitive companion of mTOR (Rictor), mLST8/GbL, and
mammalian stress-activated protein kinase interacting protein 1
(mSIN1) to form mTOR complex 2 (mTORC2) [3,4].
The upstream phosphatidylinositol 3-kinase (PI3K) signaling
pathway can activate mTOR. Class IA PI3Ks are activated by
growth factor receptor tyrosine kinases (RTKs) and are composed
of a heterodimer consisting of a p110a/p110b catalytic and a p85
regulatory subunit [5]. The PIK3CA (phosphatidylinositol 3-kinase,
catalytic, a-polypeptide) gene that encodes p110a is frequently
mutated in many human cancers, including CRC [6]. Point
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domain (exon 9) and H1047R in the catalytic kinase domain (exon
20). These mutations increase p110a activity and promote CRC
cell growth, invasion, and migration in vitro via activation of the
PI3K pathway [7]. Mutations in the helical and catalytic domains
of PIK3CA confer essentially identical phenotypes in human CRC
cell lines [7]. AKT is a critical downstream effector of the PI3K
pathway and promotes cell growth and survival via a number of
mechanisms, including phosphorylation of TSC2, which results in
mTORC1 activation [5]. Full activation of AKT is achieved after
phosphorylation at Thr308 and Ser473 by PDK1 and mTORC2,
respectively [5,8–11].
Because of its central role in carcinogenesis, mTORC1
blockade is an attractive therapeutic strategy for CRC. Treatment
of Apc D716 mice with the mTORC1 inhibitor everolimus inhibits
cellular proliferation and tumor angiogenesis, resulting in a
decrease in both number and size of intestinal tumors [12]. We
have recently reported that treatment of a genetically engineered
mouse (GEM) model for sporadic CRC with the mTORC1
inhibitor rapamycin results in an 80% reduction in individual
tumor growth, as observed by longitudinal colonoscopy surveil-
lance [11]. However, the clinical efficacy of mTORC1 blockade
may be attenuated by the concomitant loss of an mTORC1-
dependent negative feedback loop on PI3K signaling (reflected by
increased AKT phosphorylation at Thr308), and continued
mTORC2-mediated activation of AKT through phosphorylation
at Ser473 [9–14]. Indeed, a Phase I clinical trial examining the
efficacy of the mTORC1 inhibitor everolimus in advanced solid
tumors demonstrated modest benefit in only one of 16 colorectal
cancer patients and overall increased phosphorylation of AKT at
Ser473 [13]. Taken together, it appears that therapeutic strategies
in which PI3K and mTOR are concurrently inhibited may be
most efficacious.
NVP-BEZ235 (Novartis) is a dual pan-class I PI3K and mTOR
kinase inhibitor that has been demonstrated to reduce tumor
growth in a number of different xenograft and several genetically
engineered mouse (GEM) models and is currently in clinical trials
[14–50]. There has been suggestion that use of such agents may be
limited to tumors with activating mutations in PIK3CA [51,52]. As
activating PIK3CA mutations are seen in only 17% of CRC, this
would imply such agents may be targeted towards only a small
proportion of patients [53]. Because NVP-BEZ235 inhibits the
wild-type and mutant forms of PIK3CA with comparable efficacy
[32], we hypothesized that NVP-BEZ235 may have significant
efficacy in the treatment of PIK3CA wild-type CRC.
In this manuscript, we describe results from in vitro treatment
studies demonstrating comparable efficacy of NVP-BEZ235
against both PIK3CA mutant and wild-type human CRC cell
lines. We also describe results from in vivo treatment studies
demonstrating significant efficacy in a GEM model for sporadic
wild-type PIK3CA CRC. Taken together, our findings provide a
compelling preclinical rationale for clinical trials to examine the
use of NVP-BEZ235 in treatment of PIK3CA wild-type CRC
patients.
Materials and Methods
In vitro treatment of human CRC cell lines
HCT116 (PIK3CA mutant; kinase domain at H1047R), DLD-1
(PIK3CA mutant; helical domain at E545K), and SW480 (PIK3CA
wild-type) human CRC cell lines (ATCC) and isogenic DLD-1
PIK3CA mutant and wild-type cells (obtained from B. Vogelstein)
were maintained in DMEM (Invitrogen) with 10% FBS and 16
Penicillin/Streptomycin (Invitrogen). Cells were plated at different
initial densities (HCT116: 3,000 cells/well, DLD-1: 5,500 cells/
well, SW480: 4,500 cells/well, DLD-1 PIK3CA mutant: 7,000
cells/well, and DLD-1 PIK3CA wild-type: 9,000 cells/well) to
account for differential growth kinetics. After 16 hours, cells were
incubated with increasing concentrations of NVP-BEZ235 (No-
vartis), and drug-containing growth medium was changed every
24 hours. Cell viability was assessed 16 hours after the initial
plating and 48 hours after initiation of drug treatment using the
colorimetric MTS assay CellTiter 96H AQueous One Solution
Cell Proliferation Assay (Promega), as per the manufacturer’s
instructions. Cell viability after drug treatment was normalized to
that of untreated cells also grown for 48 hours. IC50 values were
calculated using 4 parameter nonlinear regression in GraphPad
Prism 5 (GraphPad Software). For western blot analysis, cells were
plated with 0 nM or maximal inhibitory dose (500 nM) NVP-
BEZ235 for 2, 6, 24, or 48 hours.
Sequencing of colonic tumors from a GEM model for
sporadic CRC
C57BL/6J Apc conditional knockout mice (Apc CKO) were
treated with Adeno-Cre, as previously described [11]. Following
necropsy, 10 tumor specimens were collected in 1 ml RNA Later
(Invitrogen, Inc), stored overnight in 4uC, then removed from
RNA Later and archived in 280uC. RNA was extracted from
specimens using RNeasy (Qiagen, Inc.), and cDNA was generated
with reverse transcriptase (Omniscript RT, Qiagen, Inc). Primers
designed by the study authors were used to create 553 bp and
477 bp amplicons (PCR performed using Platinum PCR Super-
Mix High Fidelity, Invitrogen, Inc) spanning codons 532–554 of
exon 9 (helical domain; 9F: 59 GCAGTGTGGTGAAGTTTCCA
39, 9R: 59 TGGCCAATCCTTTGATTTGT 39) and c1011–1062
of exon 20 (kinase domain; 20F: 59 ACTGCGTGGCAACCTT-
TATC 39, 20R: 59 TGATGGTGTGGAAGATCCAA 39) of the
Pik3ca gene, respectively, which include mutation hotspot regions.
Sanger sequencing of the amplicons was performed at the
BioPolymers Facility at Harvard Medical School, and results
analyzed with Sequencher 4.10.1 (Gene Codes, Inc).
In vivo treatment of a GEM model for sporadic CRC
Apc CKO mice were treated with Adeno-Cre and followed by
optical colonoscopy, as previously described [11]. As a colono-
scopic metric for tumor size, the Tumor Size Index (TSI) was
calculated as (tumor area/colonic lumen area)6100 (%). Tumor-
bearing mice were randomly assigned to treatment with either
control vehicle alone (n=8) or 45 mg/kg body weight NVP-
BEZ235 in 10% 1-methyl-2-pyrrolidone/90% PEG 300 (n=8) by
daily oral gavage for 28 days. The treatment dose was chosen
based on literature indicating that 40–50 mg/kg body weight
NVP-BEZ235 effectively treats murine tumor models without
adverse effects [15,24,26,28,32,47]. Based on pharmacokinetic
studies demonstrating maximal tissue concentration one hour after
NVP-BEZ235 administration, tumor-bearing mice were sacrificed
one hour after final treatment dose [32]. Colonic tumor volume
was assessed using calipers (width6length6height) and tumors
were harvested for both western blot analysis and immunohisto-
chemistry.
Western blot analysis
Concentrations of whole cell or tumor lysates were determined
by Bio-Rad Protein Assay (Bio-Rad). 10 mg and 25 mg protein
lysate for whole cell and tumor, respectively, was separated on
10% SDS/PAGE gel, transferred to nitrocellulose membrane,
blocked in 1% BSA for one hour, incubated at room temperature
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antibody. Detection was performed using the Amersham
TM
ECL
TM Western Blot Detection Reagents (GE Healthcare). p-
AKT Thr308 (1:1000 dilution), p-AKT Ser473 (1:2000 dilution),
total AKT (1:1000 dilution), p-S6 Ser240/244 (1:3000 dilution), p-
S6 Ser235/236 (1:1000 dilution), S6 (1:1000 dilution), cleaved
caspase 3 (1:1000 dilution), and cleaved PARP (1:1000 dilution)
were obtained from Cell Signaling Technologies (Beverly, MA). b-
actin (1:5000 dilution) was obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA). Peroxidase AffiniPure Donkey Anti- Rabbit
Ig secondary antibody (1:10,000 dilution) was obtained from
Jackson ImmunoResearch (West Grove, PA) [11].
Immunohistochemistry
Five mm paraffin-embedded tissue sections were deparaffinized
in xylene followed by alcohol rehydration. Antigen retrieval was
performed in 16citrate buffer (pH 6.0) (Zymed) using a Medical
Decloaking Chamber (Biocare Medical). Slides were blocked at
room temperature with Peroxidase Blocking Reagent (DAKO),
normal donkey/rabbit serum, and Avidin/Biotin Blocking Kit
(Vector Laboratories). Slides were incubated overnight at 4uC with
primary antibody and 30 minutes at room temperature with
secondary antibody. The Vectastain ABC kit (Vector Laborato-
ries) was used for detection per manufacturer’s instructions. Slides
were stained with the Liquid DAB+Substrate Chromogen System
(Dako) per manufacturer’s instructions and counterstained with
Mayer’s hematoxylin solution and Scott’s Bluing solution. p-AKT
Ser473 (1:50 dilution), p-S6 Ser240/244 (1:50 dilution), p-S6
Ser235/236 (1:100 dilution), were obtained from Cell Signaling
Technologies (Beverly, MA). CD31 (1:100 dilution) was obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). KI-67 (1:100
dilution) was obtained from US Biological (Swampscott, MA).
TUNEL assay (Apoptag) was purchased from Millipore (Billerica,
MA) [11]. The KI-67 proliferation index was calculated as the
mean number of KI-67 positive cells/total number of glandular
cells per high power field (mean of 16 high power fields)6100, and
microvessel density (MVD) was calculated as number of CD31
positive cells per high power field (mean of 16 high power fields).
TUNEL positivity index was calculated as mean number of
TUNEL positive cells/total number of glandular cells per high
power field (mean of 16 high power fields)6100. Measurements
were performed by three blinded, independent observers in four
control and four treated tumors.
Statistics
Comparisons of final tumor volume, KI-67, MVD, and
apoptotic cells between control and NVP-BEZ235-treated cohorts
were calculated using the two-tailed Independent-Samples T Test.
Pre- and post-treatment TSI values were compared with the
Wilcoxon signed-rank test. P,0.05 was considered significant for
all analyses. All analyses were calculated using SPSS 18.0 for
Windows (IBM, Inc).
Results
In vitro NVP-BEZ235 treatment of human CRC cell lines
decreases cellular proliferation but has no effect on
apoptosis
To examine the effects of in vitro NVP-BEZ235 treatment on
cellular viability, three human CRC cell lines (HCT116, DLD-1,
and SW480) were treated with increasing amounts of NVP-BEZ235
for 48 hours, and cellular viability was assessed by a colorimetric
MTS assay. These studies revealed a similar dose-dependent
decrease in viability after NVP-BEZ235 treatment (mean IC50 of
three separate experiments=14.366.4, 9.061.5, and 12.061.6 nM
for HCT116, DLD-1, and SW480 cell lines, respectively; p=0.74)
for all three cell lines (Figure 1A). To determine if the observed
decrease in cellular viability after NVP-BEZ235 treatment resulted
from an induction of apoptosis, western blot analysis for cleaved
caspase-3 and cleaved PARP was performed, revealing no increase
intheseapoptoticmarkerswithNVP-BEZ235treatment(Figure1B).
Taken together, these studies suggest that in vitro treatment with
NVP-BEZ235 results in an equivalent decrease in cellular
proliferation in two CRC cell lines harboring distinct PIK3CA
mutations (HCT116 and DLD-1) as well as in a PIK3CA wild-type
colorectal cancer cell (SW480), with no effect on apoptosis.
In vitro NVP-BEZ235 treatment of human CRC cell lines
results in sustained mTORC1 and mTORC2 inhibition, but
transient PI3K blockade
To examine the effects of in vitro NVP-BEZ235 treatment on
PI3K (p-AKT
Thr308), mTORC1 (p-S6
Ser235/236 and p-S6
Ser240/244),
and mTORC2 (p-AKT
Ser473) mTOR signaling, western blot
analysis was performed. After two hours of NVP-BEZ235
treatment, levels of p-AKT
Thr308, p-AKT
Ser473, p-S6
Ser235/236,
and p-S6
Ser240/244 were all significantly decreased. Whereas a
sustained decrease was observed in the levels of p-AKT
Ser473,p -
S6
Ser235/236, and p-S6
Ser240/244, full inhibition of p-AKT
Thr308 was
lost in as little as six hours (Figure 1B). Taken together, these results
suggest that in vitro NVP-BEZ235 treatment results in sustained
inhibition of mTORC1 and mTORC2 signaling, but that PI3K
blockade is transient.
The efficacy of in vitro NVP-BEZ235 treatment of human
CRC cell lines does not depend on PIK3CA mutational
status
The comparable efficacy of NVP-BEZ235 treatment in
PIK3CA mutant (HCT116 and DLD-1) and PIK3CA wild type
(SW480) human CRC cell lines suggests that its clinical efficacy
might not be limited to those patients whose tumors contain
activating PIK3CA mutations. To further examine this possibility,
we assessed the effect of NVP-BEZ235 on cellular proliferation
and intracellular cell signaling in paired PIK3CA mutant and
wild-type cell lines. The PIK3CA mutant cell line was derived
from DLD-1 through disruption of the wild-type PIK3CA allele by
targeted homologous recombination, whereas the PIK3CA wild-
type cell line was derived through disruption of the mutant
PIK3CA allele (a kind gift from B. Vogelstein) [7]. As such, the
genetic composition of these cells differs only at the PIK3CA locus,
making these otherwise perfect isogenic controls. We found
similar IC50’s for NVP-BEZ235 in both PIK3CA mutant and
wild-type DLD-1 cells (mean IC50 of three separate experi-
ments=15.166.0 and 12.164.3 nM for DLD-1 PIK3CA mutant
and wild-type cell lines, respectively; p=0.82, Figure 2A).
Western blot analysis of p-AKT and p-S6 revealed sustained
inhibition of p-AKT
Ser473,p - S 6
Ser235/236, and p-S6
Ser240/244;
however, the inhibition of p-AKT
Thr308 was transient in both cell
lines (Figure 2B). Furthermore, NVP-BEZ235 treatment did not
increase levels of cleaved caspase-3 and cleaved PARP in either
cell line (Figure 2B). Overall, these findings suggest that PIK3CA
mutational status does not predict the efficacy of NVP-BEZ235
treatment in human CRC cell lines.
In vivo NVP-BEZ235 treatment induces tumor regression
in a GEM model for sporadic PIK3CA wild-type CRC
To examine the effects of in vivo NVP-BEZ235 treatment on
colonic tumor growth, we used a novel GEM model for sporadic
PI3K/mTOR Blockade in Colorectal Cancer
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Cre recombinase (Adeno-Cre) was used to induce colonic tumors
in floxed Apc mice. Tumors from 10 mice were analyzed for the
presence of activating mutations by direct sequencing of exons 9
and 20 of the Pik3ca gene. No mutations were identified, which
suggests that these mice are representative of PIK3CA wild-type
CRC. Optical colonoscopy was used to randomize treatment of
comparably sized colonic tumors with control drug vehicle or
45 mg/kg NVP-BEZ235 by daily oral gavage for 28 days. We
noted no toxicity or side effects during this drug treatment
regimen. Subsequent longitudinal growth or regression of
individual colonic tumors was determined by optical colonoscopy,
as previously described [11]. For each tumor, a relative Tumor
Size Index (TSI) metric was calculated as tumor size (T)
normalized to colonic luminal area (L) (Figure 3A).
A representative time course of colonoscopy images for control
(n=8) and NVP-BEZ235-treated tumors (n=8) is shown in
Figure 3B. Tumor volume at necropsy was significantly larger in
control vs. treated groups (65 mm
3 vs. 5 mm
3; p=0.01;
Figure 3C). In accordance with our previous analyses [11], the
final TSI in both treatment groups positively correlated with
tumor volume at necropsy (R
2=0.89, p=0.0001; Figure 3D). The
mean TSI in the control group significantly increased over the
treatment period (32% pre-treatment vs. 57% post-treatment,
p=0.01; Figure 3E), whereas that in the NVP-BEZ235 cohort
significantly decreased (36% vs. 20%, p=0.008; Figure 3F). Every
Figure 1. NVP-BEZ235 treatment results in decreased cell viability, transient PI3K blockade inhibition, and sustained mTORC1/
mTORC2 blockade. (A) Cell viability of HCT116, DLD-1, and SW480 CRC cell lines was assessed by MTS assay after treatment with increasing
concentrations (0–500 nM) of NVP-BEZ235 for 48 hours. Results shown are the mean of three independent experiments. (B) Western blot analysis for
p-AKT
Thr308, p-AKT
Ser473, p-S6
Ser240/244, p-S6
Ser235/236, cleaved caspase 3, and cleaved PARP was performed after 2, 6, 24, and 48 hours incubation with
(2) 0 or (+) 500 nM NVP-BEZ235.
doi:10.1371/journal.pone.0025132.g001
PI3K/mTOR Blockade in Colorectal Cancer
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decreased in size. Taken together, these results demonstrate that in
vivo treatment with NVP-BEZ235 results in significant regression
in PIK3CA wild-type colonic tumors.
In vivo NVP-BEZ235 treatment of a GEM model for
sporadic CRC results in sustained mTORC1 and mTORC2
inhibition, but transient PI3K blockade
To examine the effects of in vivo NVP-BEZ235 treatment on
PI3K and mTOR signaling, western blot analysis was performed
in colonic tumors that were harvested one hour after final drug
dosing on days 5 and 28 of treatment. Western blot analysis for
levels of p-AKT
Thr308, p-S6
Ser240/244, and p-AKT
Ser473 was
performed as surrogates for activation of the PI3K, mTORC1,
and mTORC2 pathways, respectively. A sustained decrease in
levels of p-AKT
Ser473 and p-S6
Ser240/244 was observed in the
tumors of mice treated with NVP-BEZ235, as compared to control
diluent (Figure 4A and 4B). These findings were confirmed by
tumor immunohistochemistry (Figure 4C). As with our in vitro
studies, an initial decrease in levels of p-AKT
Thr308 was observed
at five days after treatment, but normalized by 28 days (Figures 4A
and 4B). Taken together, these results suggest that in vivo NVP-
BEZ235 treatment results in sustained inhibition mTORC1 and
mTORC2, but transient PI3K blockade.
In vivo NVP-BEZ235 treatment of a GEM model for
sporadic CRC inhibits proliferation, has no effect on
apoptosis, and blocks tumor angiogenesis
To examine the effects of in vivo NVP-BEZ235 treatment on
cellular proliferation, colonic tumors were examined by immuno-
histochemistry for the proliferation marker KI-67. This analysis
revealed that proliferation decreased by 56% after 28 days of NVP-
BEZ235 treatment (p=0.003, Figure 5A). To assess the effect of
NVP-BEZ235 treatment on cellular apoptosis, colonic tumors were
examined by TUNEL assay. No differences were seen between
tumors treated with control diluent and NVP-BEZ235 (p=0.9,
Figure 5B). As the PI3K and mTOR pathways play a significant
role intumorangiogenesis [54,55],weexaminedtheeffectsofNVP-
BEZ235 treatment on microvessel density (MVD) through
immunohistochemistry for the endothelial marker CD31. This
analysis revealed that MVD decreased by 75% after 28 days of
NVP-BEZ235 treatment (p=0.013, Figure 5C). Taken together,
these results suggest that in vivo treatment with NVP-BEZ235 results
in a significant decrease in tumor proliferation, does not induce
cellular apoptosis, and inhibits tumor angiogenesis.
Discussion
Because of their central role in the initiation and progression of
CRC, blockade of the mTOR and PI3K signaling pathways has
Figure 2. Effects of NVP-BEZ235 on cell viability and PI3K/mTOR signaling are independent of PIK3CA status. (A) Cell viability of mutant
and wild-type isogenic PIK3CA cells was assessed by MTS assay after treatment with increasing concentrations (0–500 nM) of NVP-BEZ235 for
48 hours. Results shown are the mean of four independent experiments. (B) Western blot analysis for p-AKT
Thr308, p-AKT
Ser473, p-S6
Ser240/244,p -
S6
Ser235/236, cleaved caspase 3, and cleaved PARP was performed after 2, 6, 24, and 48 hours incubation with (2) 0 or (+) 500 nM NVP-BEZ235.
doi:10.1371/journal.pone.0025132.g002
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therapeutics [10,56–59]. We and others have demonstrated the
efficacy of mTORC1 pathway inhibition in preclinical CRC
models [11,12]. However, an early clinical trial examining
mTORC1 inhibitors in human CRC patients demonstrated
modest results, perhaps due to loss of an mTORC1-dependent
feedback loop that limits PI3K activation and/or continued
mTORC2-mediated activation of AKT [3,60]. Taken together, it
appears dual PI3K/mTOR inhibitors, such as NVP-BEZ235, are
required for maximal therapeutic efficacy.
Some studies have suggested that PIK3CA mutant cancers are
‘‘oncogenically addicted’’ to PI3K signaling, leading to increased
sensitivity to PI3K inhibitor therapy [7,61,62]. However, one
group has reported no association between PIK3CA mutational
status and response to PI3K inhibitors [63]. Nonetheless, another
group has reported exclusively targeting PIK3CA mutant patients
for PI3K/mTOR therapy [64]. As PIK3CA mutations are seen in
only 17% of human CRC, this approach would significantly limit
the clinical impact of such agents [53]. Because NVP-BEZ235
equally inhibits the mutant and wild-type forms of PIK3CA,w e
Figure 3. In vivo treatment of a GEM model for sporadic CRC results in tumor regression. Mice with colonic tumors were randomized to
treatment with control diluent (N=8) or 45 mg/kg NVP-BEZ235 (N=8) by daily oral gavage for 28 days. Resulting colonic tumor growth or regression
was serially examined by optical colonoscopy. (A) Tumor Size Index (TSI) was calculated as Tumor Area (T) divided by Lumen Area (L) 6100. (B)
Representative tumor colonoscopy still images during the 28 day treatment period. (C) Tumor volume of control and NVP-BEZ235-treated tumors at
necropsy (mean 65 mm
3 vs. 5 mm
3; p=0.01). (D) Final TSI vs. Tumor Volume (R
2=0.89, P,0.0001). Change in mean TSI for (E) control (32% pre-
treatment vs. 57% post-treatment, P=0.01) and (F) treated (32% vs. 20%, P=0.02) cohorts.
doi:10.1371/journal.pone.0025132.g003
PI3K/mTOR Blockade in Colorectal Cancer
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e25132Figure 4. In vivo NVP-BEZ235 treatment of a GEM model for sporadic CRC results in transient PI3K blockade inhibition and
sustained mTORC1/mTORC2 blockade. Mice with colonic tumors were randomized to treatment with control diluent or 45 mg/kg NVP-BEZ235
by daily oral gavage for five days. Western blot analysis of p-AKT
Thr308, p-AKT
Ser473, and p-S6
Ser240/244 was performed for tumors treated with (2)
control diluent or (+) NVP-BEZ235 for (A) five and (B) 28 days. (C) Immunohistochemistry of p-AKT
Ser473, p-S6
Ser240/244, and p-S6
Ser235/236 was
performed for tumors treated with control diluent or NVP-BEZ235 for 28 days.
doi:10.1371/journal.pone.0025132.g004
PI3K/mTOR Blockade in Colorectal Cancer
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human wild-type PIK3CA CRC [32]. In support of this, we found
comparable sensitivity to in vitro NVP-BEZ235 treatment in
PIK3CA mutant (HCT116, kinase domain mutation; DLD-1,
helical domain mutation) and PIK3CA wild-type (SW480) CRC
cell lines, as well as in matched PIK3CA mutant and wild-type
isogenic cell lines. Direct sequencing of the hot spot regions at
exons 9 and 20 of Pik3ca in the colonic tumors validated our GEM
model as a surrogate for PIK3CA wild-type CRC, which we used in
our in vivo NVP-BEZ235 treatment studies. Taken together, these
findings suggest that NVP-BEZ235 treatment may have clinical
benefit in the 83% of CRC patients with wild-type PIK3CA.T o
further assess this feature, we sought to examine whether NVP-
BEZ235 would be effective in a GEM model for sporadic PIK3CA
wild-type CRC.
Traditional in vivo target validation approaches rely on xenograft
platforms. Unfortunately, these models are not truly predictive of
response in human patients, because they derive from high passage
tumor cell lines grown in vitro. These cell lines are implanted into
ectopic sites that do not resemble the colonic microenvironment,
and therefore fail to recapitulate the heterogeneous nature of cancer
and its supporting stroma [65]. Although GEM cancer models
address these shortcomings, most GEM models employ germ-line
or tissue-wide modification of genes known to be mutated in human
CRC. In addition, many CRC GEM models mainly present with
small intestinal tumors [66]. To accurately model human sporadic
CRC, we have recently described a procedure in which Adeno-Cre
is administered to floxed mice to somatically inactivate the Apc gene
in a stochastic fashion and restrict tumor formation to the distal
colon. The reproducible anatomical location of these tumors
permits the use of optical colonoscopy to examine individual
tumors in a longitudinal fashion [11].
To examine the efficacy of in vivo NVP-BEZ235 treatment, we
used our GEM model for sporadic CRC. In our studies, there was
Figure 5. In vivo NVP-BEZ235 treatment of a GEM model for sporadic CRC inhibits proliferation, has no effect on apoptosis, and
blocks tumor angiogenesis. (A) Representative immunohistochemistry for the proliferation marker KI-67 after treatment with control diluent or
NVP-BEZ2355 for 28 days (p=0.003). KI-67 proliferation index was calculated as average number of positive tumor cells per high power field. (B)
TUNEL immunohistochemistry was performed in tumors treated with control diluent or NVP-BEZ235 for 28 days (p=0.9). TUNEL staining was
quantified as percent positive cells per high powered field. (C) Representative immunohistochemistry for the endothelial marker PECAM after
treatment with control diluent or 45 mg/kg NVP-BEZ2355 (p=0.013). Microvessel density was calculated as average number of positive vessels per
high power field.
doi:10.1371/journal.pone.0025132.g005
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colonoscopy versus necropsy (R
2=0.89), thus validating our
colonoscopy-based tumor sizing protocol. In accordance with
our in vitro NVP-BEZ235 treatment of human CRC cell lines,
colonic tumors from the GEM model decreased by 43% in size
after in vivo treatment with NVP-BEZ235, whereas control tumors
increased in size by 97% (p,0.0001). Similar findings have been
reported with another dual PI3K/mTOR inhibitor, PKI-587, in a
xenograft model of CRC [67]. Taken together, these results
suggest that NVP-BEZ235 would be an effective treatment in
human CRC patients.
We studied the effect of NVP-BEZ235 treatment on the PI3K,
mTORC1, and mTORC2 signaling pathways. Both in vitro and in
vivo studies demonstrated sustained inhibition of mTORC1 and
mTORC2 (reflected in decreased phosphorylation of S6 and
AKT
Ser473, respectively), but transient blockade of PI3K activation
by PDK1 (assessed by levels of p-AKT
Thr308). These findings are
consistent with a report demonstrating the parallel roles of
mTORC1 and mTORC2 in CRC carcinogenesis [68]. Findings
from other cancer models suggest that NVP-BEZ235 prevents
mTORC2-dependent AKT
Ser473 phosphorylation, and that PI3K
inhibition with NVP-BEZ235 may be short-lived due to loss of
feedback inhibition of PI3K activity by the mTORC1 target S6
kinase [19,39,69]. Therefore, we speculate that the addition of a
selective PI3K inhibitor with efficacy against wild-type and mutant
PIK3CA may augment the effectiveness of NVP-BEZ235 therapy.
Taken together, our findings suggest that the efficacy of NVP-
BEZ235 may derive predominantly from inhibition of mTORC1
and mTORC2 signaling.
We also examined possible mechanisms by which NVP-BEZ235
might induce tumor regression. In vivo NVP-BEZ235 treatment of
colonic tumors resulted in a 56% decrease in cellular proliferation,
but the absence of an induction in apoptosis. Although induction
of apoptosis by NVP-BEZ235 treatment has been reported in
lung, breast, renal cell carcinoma, and ovarian models [26,39,47],
the absence of apoptosis has been found after treatment of glioma
and sarcoma models [36,39]. Furthermore, in vivo NVP-BEZ235
treatment of colonic tumors resulted in a 75% decrease in
microvessel density after NVP-BEZ235 treatment. Similar findings
have been described in pancreatic, glioma, and neuroendocrine
tumor systems [19,39,54]. It is interesting that though we observed
a decrease in macroscopic tumor size after in vivo NVP-BEZ235
treatment, we did not see a corresponding induction of apoptosis.
This finding could be explained by an increase in constitutive cell
turnover resulting from a drug-induced inhibition of angiogenesis
coupled to a simultaneous drug-induced decrease in cellular
proliferation. Because this process occurred slowly over the 28 day
time course, frank necrosis would not be seen. Taken together,
these findings support the further investigation of combination
therapy with NVP-BEZ235, cytotoxic, and/or anti-angiogenic
agents in CRC patients.
In summary, we present evidence for the therapeutic efficacy of
NVP-BEZ235 in PIK3CA wild-type CRC. Furthermore, our
results suggest that the efficacy of NVP-BEZ235 treatment may
be augmented in if used in combination with additional PI3K
inhibition, cytotoxic, and/or anti-angiogenic agents. Taken
together, our findings provide compelling evidence for the further
exploration of NVP-BEZ235-based therapies in clinical trials for
CRC.
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